Scarica l'app Stockscreener
35.20
2.95%
1.01
Dopo l'orario di chiusura:
35.20
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - Sahm
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
AGIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance Australia
Agios to seek accelerated approval in US of oral mitapivat for SCD - Sickle Cell Disease News
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
Insider sale and RSU vesting at AGIO (Nasdaq: AGIO) — 2,959 shares - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
3,280 RSUs vest; James Burns sold 5,218 shares — AGIO (NASDAQ: AGIO) - Stock Titan
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD - bitget.com
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Earnings Recap: Is Agios Pharmaceuticals Inc a good ESG investment2026 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Agios to pursue accelerated approval for mitapivat in sickle cell By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $65 - Moomoo
The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios (AGIO) Files for Accelerated Approval of Mitapivat in Sick - GuruFocus
Agios Shares Rise After Plans for Accelerated Approval Filing of Mitapivat in Sickle Cell Disease - MarketScreener
BofA raises Agios Pharma stock price target on SCD filing path By Investing.com - za.investing.com
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? - Benzinga
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - The Motley Fool
BofA raises Agios Pharma stock price target on SCD filing path - Investing.com Australia
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap UpHere's Why - marketbeat.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga
Truist reiterates Agios Pharma stock rating on accelerated approval path - Investing.com
Agios (AGIO) Sees 13% Boost Following Approval Pursuit for Mitap - GuruFocus
Agios Pharmaceuticals (AGIO) Seeks Accelerated FDA Approval for Sickle Cell Treatment - GuruFocus
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - Seeking Alpha
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - Morningstar
Agios stock surges on FDA path for mitapivat approval By Investing.com - Investing.com Canada
Agios to pursue accelerated approval for mitapivat in sickle cell - Investing.com
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA - The Manila Times
Agios moves oral sickle cell drug toward faster U.S. approval - Stock Titan
Agios Pharmaceuticals Receives 'Hold' Rating from Analysts - National Today
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Hold" from Analysts - marketbeat.com
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A. - MarketBeat
Why Agios Pharmaceuticals (AGIO) Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Pass Below 200-Day Moving AverageHere's Why - MarketBeat
Agios Pharmaceuticals leukemia drug gets U.S. approval - AOL.com
(AGIO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Agios Pharmaceuticals stock declines 23% in 6 months: Here's why - MSN
Vanguard (NYSE: V) disaggregates Agios holdings; reports 0% ownership - Stock Titan
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):